[ad_1]
The debate over how long currently approved vaccines will provide protection against the novel coronavirus is ongoing, but at least one industry giant believes that for the next few years it could be an annual, similar vaccine. to the flu shot.
“Unfortunately, as [the virus] propagates, it can also mutate, “Alex Gorsky, CEO of Johnson & Johnson at CNBC, recently told CNBC.” Every time it mutates, it’s almost like another click on the dial so to speak where we can see a another variant, another mutation which can have an impact on its ability to repel antibodies or to have a different type of response not only to a treatment but also to a vaccine. “
Johnson & Johnson’s vaccine, which is awaiting emergency use clearance from the FDA, is a single-dose vaccine that developed using adenovirus rather than mRNA technology on which Moderna and Pfizer relied. Interestingly, Johnson & Johnson’s vaccine showed 66% effectiveness in a global trial, while the other two showed around 94% to 95% effectiveness against the virus.
MOST AMERICANS ARE NOT HAPPY WITH THE COVID-19 VACCINATION PROCESS.
The company also has a two-dose vaccine in the works, but trial data is not expected until later this year, Gorsky told CNBC.
Moderna and Pfizer have both vouched for the ability of their vaccines to fend off the coronavirus variants, although Dr Anthony Fauci said the South African variant could prove to be troublesome because it has shown “clinical consequences.”
VERY LITTLE SPREAD OF COVID FOUND AT SUMMER CAMPS: STUDY
Fauci said the variants should serve as a “wake-up call” to governments and companies currently developing vaccines that it is essential “to be nimble so that you can easily adjust and easily create versions of the vaccine that are in fact specifically directed at any mutation. is in fact prevalent at all times. “
CLICK HERE FOR FULL CORONAVIRUS COVERAGE
That said, Pfizer has already touted the “flexibility” of its mRNA technology, which could easily allow adjustments to the product when needed.
[ad_2]
Source link